Loading
Life sciences · Journal article
Molecular Pharmaceutics · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Sufficient tumor uptake and retention, and high tumor-to-kidney ratio are highly relevant for fibroblast activation protein (FAP)-targeted tracers as imaging companions for theranostic development. Although FAP-2286 improves tumor retention versus early-generation FAPI tracers, its extended renal residence limits its application as a radiopharmaceutical therapy. We benchmarked FXX489, a next-generation cyclic peptide FAP ligand, against FAP-2286 preclinically and evaluated first-in-human [68Ga]Ga-FXX489 PET/CT to support its translational development for FAP-directed theranostics. [68Ga]Ga-FXX489 showed stronger FAP affinity than [68Ga]Ga-FAP-2286, including higher cellular uptake, lower efflux, and lower IC50. In HT-1080-hFAP xenografts, [68Ga]Ga-FXX489 achieved higher tumor uptake and retention on micro-PET and ex vivo biodistribution, and a higher tumor-to-kidney ratio. In patients (n = 10), [68Ga]Ga-FXX489 was well tolerated, and detected all 12 primary lesions (mean SUVmax, 11.20 ± 3.24) and all 42 metastatic lymph nodes (100% [42/42] vs 74% [31/42] for [18F]FDG, P < 0.001), while visualizing gastric cancer lesions with higher uptake than [18F]FDG in a paired comparison. [68Ga]Ga-FXX489 improves tumor retention and tumor-to-kidney ratio compared to [68Ga]Ga-FAP-2286 while maintaining specific FAP targeting. First-in-human [68Ga]Ga-FXX489 PET/CT shows promising detection of primary and metastatic lesions, supporting further clinical applications.